Seeking Alpha

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

BOSTON, Dec. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (XFOR) (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the ...
Seeking Alpha

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (XFOR) (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the ...
Nasdaq

X4 Pharmaceuticals Announces Activation of Phase 3 4WARD Trial for Chronic Neutropenia and 2024 Financial Results

X4 Pharmaceuticals announced that its Phase 3 4WARD trial for chronic neutropenia is now active at around 90% of targeted sites, with expected full enrollment by Q3 or Q4 of 2025 and top-line data ...
Business Insider

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a ...
Nasdaq

X4 Pharmaceuticals Reports Progress in Phase 3 Chronic Neutropenia Trial and Financial Results for Q1 2025

X4 Pharmaceuticals has progressed significantly in its ongoing Phase 3 clinical trial, known as the 4WARD trial, targeting chronic neutropenia, aiming for full enrollment by the end of 2025 and ...
Morningstar

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in combination therapy BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 ...